Neuramedy Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Series A
- Investors
-
8
Neuramedy General Information
Description
Developer of antibodies designed for the cure of neurodegenerative diseases. The company specializes in providing cures for Parkinson's and Alzheimer's disease, enabling clients to develop therapeutic solutions and chemical drugs by utilizing patent-protected efficacy monitoring systems.
Contact Information
Website
neuramedy.comCorporate Office
- Number 402, 20, Gwangnaru-ro 6-gil
- Seoul, Seongdong 03100
- South Korea
Corporate Office
- Number 402, 20, Gwangnaru-ro 6-gil
- Seoul, Seongdong 03100
- South Korea
Neuramedy Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series A) | 20-Jul-2020 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 28-Oct-2019 | Completed | Startup | |||
| 1. Accelerator/Incubator | 31-Jan-2019 | Completed | Startup |
Neuramedy Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Neuramedy Patents
Neuramedy Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4722244-A1 | Anti-tlr2 antibody and use thereof | Pending | 09-May-2023 | ||
| WO-2024232454-A1 | Anti-tlr2 antibody and use thereof | Inactive | 09-May-2023 | ||
| EP-3583949-A1 | Toll-like receptor 2 (tlr2) antagonists for the treatment of ovarian cancer | Inactive | 19-Jun-2018 | ||
| EP-3548081-A1 | Methods and compositions for the treatment of myelodysplastic syndrome | Active | 02-Dec-2016 | ||
| EP-3548081-B1 | Methods and compositions for the treatment of myelodysplastic syndrome | Active | 02-Dec-2016 | C07K16/2896 |
Neuramedy Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Neuramedy Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Devsisters Ventures | Corporate Venture Capital | Minority | ||
| DK&D | Corporation | Minority | ||
| Korea Development Bank | VC-Backed Company | Minority | ||
| Solidus Investment | Venture Capital | Minority | ||
| STIC Ventures | Venture Capital | Minority |
Neuramedy FAQs
-
When was Neuramedy founded?
Neuramedy was founded in 2019.
-
Where is Neuramedy headquartered?
Neuramedy is headquartered in Seoul, South Korea.
-
What is the size of Neuramedy?
Neuramedy has 3 total employees.
-
What industry is Neuramedy in?
Neuramedy’s primary industry is Drug Discovery.
-
Is Neuramedy a private or public company?
Neuramedy is a Private company.
-
What is Neuramedy’s current revenue?
The current revenue for Neuramedy is .
-
How much funding has Neuramedy raised over time?
Neuramedy has raised $2.95M.
-
Who are Neuramedy’s investors?
Devsisters Ventures, DK&D, Korea Development Bank, Solidus Investment, and STIC Ventures are 5 of 8 investors who have invested in Neuramedy.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
